CDMOs offering Lentiviral Vector Manufacturing with Cell Therapy in Europe
8 matching organizations
Lentiviral Vector Manufacturing with Cell Therapy in Europe is a frequent shortlist pattern for sponsors evaluating CDMO partners with regional footprint. This page lists organizations that map to all three dimensions so you can move from broad taxonomy browsing to a geography-aware candidate set.
Profiles emphasize fit-first discovery: review scope, regulatory posture, and provenance on each listing rather than treating this page as a single ranked recommendation.
When you need additional filters (indications, claim status, or free-text search), continue to the main search experience and layer criteria on top of this starting point.
- AGC Biologics
Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- Catalent
Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
- Cell and Gene Therapy Catapult
UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
- Charles River Laboratories
Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
- Oxford Biomedica
Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Porton Advanced
End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
- WuXi Advanced Therapies
Cell & gene therapy CDMO offering discovery, process development, analytical development, cell banking, clinical and commercial manufacturing, plus biosafety testing for biologics, mAbs, vaccines, and CGT developers.
Markdown mirror: /explore/svc_lentivirus_manufacturing/mod_cell_therapy/europe.md